Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 5/20 | 0.49 |
| ▸ | NPY1R | P25929 | 4/20 | 0.49 |
| ▸ | NPY2R | P49146 | 4/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.49 |
| ▸ | GLP1R | P43220 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | TFPI | P10646 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461991 | 0.96 | C5AR1 (0.54) | C5AR1IL23RGLP1ROPRD1TFPI | |
| SCHEMBL29540550 | 0.95 | C5AR1 (0.54) | C5AR1IL23RGLP1RTFPI | |
| SCHEMBL29883702 | 0.93 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL30463393 | 0.91 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31680257 | 0.90 | C5AR1 (0.58) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL8894013 | 0.86 | TFPI (0.58) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL29936549 | 0.85 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30427476 | 0.85 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL5500011 | 0.84 | C5AR1 (0.58) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL5500020 | 0.84 | C5AR1 (0.58) | NPY4RNPY1RNPY2RNPY5RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12268724-B2 | Methods and compositions for the prevention or treatment of Barth Syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240156892-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11771734-B2 | Methods and compositions for the prevention or treatment of Barth syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | ARG2, ARGLU1, BCAT1 | NPY4R 2600/4885NPY1R 872/4885NPY2R 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.